Tryptophan 2,3-dioxygenase (TDO) inhibitors. 3-(2-(pyridyl)ethenyl)indoles as potential anticancer immunomodulators

E. Dolušić, P. Larrieu, L. Moineaux, V. Stroobant, L. Pilotte, D. Colau, L. Pochet, B. Van Den Eynde, B. Masereel, J. Wouters, R. Frédérick

Résultats de recherche: Contribution à un journal/une revueArticle

Résumé

Tryptophan catabolism mediated by indoleamine 2,3-dioxygenase (IDO) is an important mechanism of peripheral immune tolerance contributing to tumoral immune resistance. IDO inhibition is thus an active area of research in drug development. Recently, our group has shown that tryptophan 2,3-dioxygenase (TDO), an unrelated hepatic enzyme also catalyzing the first step of tryptophan degradation, is also expressed in many tumors and that this expression prevents tumor rejection by locally depleting tryptophan. Herein, we report a structure-activity study on a series of 3-(2-(pyridyl)ethenyl)indoles. More than 70 novel derivatives were synthesized, and their TDO inhibitory potency was evaluated. The rationalization of the structure-activity relationships (SARs) revealed essential features to attain high TDO inhibition and notably a dense H-bond network mainly involving His and Thr residues. Our study led to the identification of a very promising compound (58) displaying good TDO inhibition (K = 5.5 μM), high selectivity, and good oral bioavailability. Indeed, 58 was chosen for preclinical evaluation.
langue originaleAnglais
Pages (de - à)5320-5334
Nombre de pages15
journalJournal of Medicinal Chemistry
Volume54
Numéro de publication15
Les DOIs
étatPublié - 11 août 2011
EvénementBOSS XIII - 13th Belgian Organic Synthesis Symposium Louvain, 15 - 20 juillet 2012 - Leuven, Belgique
Durée: 15 juil. 201220 juil. 2012

Empreinte digitale

Tryptophan Oxygenase
Indoles
Immunologic Factors
Tryptophan
Indoleamine-Pyrrole 2,3,-Dioxygenase
Peripheral Tolerance
Immune Tolerance
Structure-Activity Relationship
Biological Availability
Neoplasms
Liver
Enzymes
Research
Pharmaceutical Preparations

Citer ceci

@article{cff33339cf444c309ce50e0075935f29,
title = "Tryptophan 2,3-dioxygenase (TDO) inhibitors. 3-(2-(pyridyl)ethenyl)indoles as potential anticancer immunomodulators",
abstract = "Tryptophan catabolism mediated by indoleamine 2,3-dioxygenase (IDO) is an important mechanism of peripheral immune tolerance contributing to tumoral immune resistance. IDO inhibition is thus an active area of research in drug development. Recently, our group has shown that tryptophan 2,3-dioxygenase (TDO), an unrelated hepatic enzyme also catalyzing the first step of tryptophan degradation, is also expressed in many tumors and that this expression prevents tumor rejection by locally depleting tryptophan. Herein, we report a structure-activity study on a series of 3-(2-(pyridyl)ethenyl)indoles. More than 70 novel derivatives were synthesized, and their TDO inhibitory potency was evaluated. The rationalization of the structure-activity relationships (SARs) revealed essential features to attain high TDO inhibition and notably a dense H-bond network mainly involving His and Thr residues. Our study led to the identification of a very promising compound (58) displaying good TDO inhibition (K = 5.5 μM), high selectivity, and good oral bioavailability. Indeed, 58 was chosen for preclinical evaluation.",
author = "E. Dolušić and P. Larrieu and L. Moineaux and V. Stroobant and L. Pilotte and D. Colau and L. Pochet and {Van Den Eynde}, B. and B. Masereel and J. Wouters and R. Fr{\'e}d{\'e}rick",
year = "2011",
month = "8",
day = "11",
doi = "10.1021/jm2006782",
language = "English",
volume = "54",
pages = "5320--5334",
journal = "J. Med. Chem.",
issn = "0022-2623",
publisher = "American Chemical Society",
number = "15",

}

Tryptophan 2,3-dioxygenase (TDO) inhibitors. 3-(2-(pyridyl)ethenyl)indoles as potential anticancer immunomodulators. / Dolušić, E.; Larrieu, P.; Moineaux, L.; Stroobant, V.; Pilotte, L.; Colau, D.; Pochet, L.; Van Den Eynde, B.; Masereel, B.; Wouters, J.; Frédérick, R.

Dans: Journal of Medicinal Chemistry, Vol 54, Numéro 15, 11.08.2011, p. 5320-5334.

Résultats de recherche: Contribution à un journal/une revueArticle

TY - JOUR

T1 - Tryptophan 2,3-dioxygenase (TDO) inhibitors. 3-(2-(pyridyl)ethenyl)indoles as potential anticancer immunomodulators

AU - Dolušić, E.

AU - Larrieu, P.

AU - Moineaux, L.

AU - Stroobant, V.

AU - Pilotte, L.

AU - Colau, D.

AU - Pochet, L.

AU - Van Den Eynde, B.

AU - Masereel, B.

AU - Wouters, J.

AU - Frédérick, R.

PY - 2011/8/11

Y1 - 2011/8/11

N2 - Tryptophan catabolism mediated by indoleamine 2,3-dioxygenase (IDO) is an important mechanism of peripheral immune tolerance contributing to tumoral immune resistance. IDO inhibition is thus an active area of research in drug development. Recently, our group has shown that tryptophan 2,3-dioxygenase (TDO), an unrelated hepatic enzyme also catalyzing the first step of tryptophan degradation, is also expressed in many tumors and that this expression prevents tumor rejection by locally depleting tryptophan. Herein, we report a structure-activity study on a series of 3-(2-(pyridyl)ethenyl)indoles. More than 70 novel derivatives were synthesized, and their TDO inhibitory potency was evaluated. The rationalization of the structure-activity relationships (SARs) revealed essential features to attain high TDO inhibition and notably a dense H-bond network mainly involving His and Thr residues. Our study led to the identification of a very promising compound (58) displaying good TDO inhibition (K = 5.5 μM), high selectivity, and good oral bioavailability. Indeed, 58 was chosen for preclinical evaluation.

AB - Tryptophan catabolism mediated by indoleamine 2,3-dioxygenase (IDO) is an important mechanism of peripheral immune tolerance contributing to tumoral immune resistance. IDO inhibition is thus an active area of research in drug development. Recently, our group has shown that tryptophan 2,3-dioxygenase (TDO), an unrelated hepatic enzyme also catalyzing the first step of tryptophan degradation, is also expressed in many tumors and that this expression prevents tumor rejection by locally depleting tryptophan. Herein, we report a structure-activity study on a series of 3-(2-(pyridyl)ethenyl)indoles. More than 70 novel derivatives were synthesized, and their TDO inhibitory potency was evaluated. The rationalization of the structure-activity relationships (SARs) revealed essential features to attain high TDO inhibition and notably a dense H-bond network mainly involving His and Thr residues. Our study led to the identification of a very promising compound (58) displaying good TDO inhibition (K = 5.5 μM), high selectivity, and good oral bioavailability. Indeed, 58 was chosen for preclinical evaluation.

UR - http://www.scopus.com/inward/record.url?scp=79961217268&partnerID=8YFLogxK

U2 - 10.1021/jm2006782

DO - 10.1021/jm2006782

M3 - Article

AN - SCOPUS:79961217268

VL - 54

SP - 5320

EP - 5334

JO - J. Med. Chem.

JF - J. Med. Chem.

SN - 0022-2623

IS - 15

ER -